OBJECTIVE: To measure total tumour volume (TTV) and dominant TV (DTV) in radical prostatectomy (RP) specimens from patients predicted to have low-volume, low-grade (LV/LG) prostate cancer, as this entity can be predicted from biopsy findings and prostate-specific antigen (PSA) level, but tumour under-sampling remains a challenge in active surveillance programmes. PATIENTS AND METHODS: This was a retrospective study from an academic centre, of men with prostate cancer treated from 2000 to 2007, with a PSA level of <10 ng/mL and one core of cancer from an extended scheme showing either Gleason score (GS) 3 + 3 of <3.0 mm or 3 + 4 of <2.0 mm. All men had RP, and the TTV, DTV, tumour location, pathological GS and stage were measured. RESULTS: Of 3055 RPs, 66 (2.1%) met the inclusion criteria. The core with cancer was from a sextant and alternative site in 26 (39%) and 40 (61%) patients, respectively. A pathological GS 3 + 3 or 3 + 4 was assigned to 94%, while 6% were GS > or = 4 + 3; all 66 tumours were organ-confined. The median (range) TTV and DTV were 0.15 (0.0008-5.06) and 0.14 (0.0008-5.04) mL, respectively. The median number of tumour foci was 3 (1-7), being unifocal in 17/66 (26%) and multifocal in 49/66 (74%). The transition zone was involved in 29% of unifocal and 71% of multifocal tumours. Of all 66 patients, the TTV was <0.5 mL in 47 (71%), and of 59 patients with biopsy GS 3 + 3, 33 (56%) had a TTV of <0.5 mL and pathological GS 3 + 3. Of 19 patients with a TTV of > or =0.5 mL, the median TTV was 1.06 (0.51-5.05) mL, with tumour foci of transition zone origin in 16 (84%). The study was limited by its retrospective design and small sample size. CONCLUSIONS: Using conservative selection criteria for predicting LV/LG cancer, RP specimens showed organ-confined disease in all cases, upgrading to GS > or = 4 + 3 in 6%, and TTV <0.5 mL in 71% of cases. The transition zone is a common location of under-sampled disease.
OBJECTIVE: To measure total tumour volume (TTV) and dominant TV (DTV) in radical prostatectomy (RP) specimens from patients predicted to have low-volume, low-grade (LV/LG) prostate cancer, as this entity can be predicted from biopsy findings and prostate-specific antigen (PSA) level, but tumour under-sampling remains a challenge in active surveillance programmes. PATIENTS AND METHODS: This was a retrospective study from an academic centre, of men with prostate cancer treated from 2000 to 2007, with a PSA level of <10 ng/mL and one core of cancer from an extended scheme showing either Gleason score (GS) 3 + 3 of <3.0 mm or 3 + 4 of <2.0 mm. All men had RP, and the TTV, DTV, tumour location, pathological GS and stage were measured. RESULTS: Of 3055 RPs, 66 (2.1%) met the inclusion criteria. The core with cancer was from a sextant and alternative site in 26 (39%) and 40 (61%) patients, respectively. A pathological GS 3 + 3 or 3 + 4 was assigned to 94%, while 6% were GS > or = 4 + 3; all 66 tumours were organ-confined. The median (range) TTV and DTV were 0.15 (0.0008-5.06) and 0.14 (0.0008-5.04) mL, respectively. The median number of tumour foci was 3 (1-7), being unifocal in 17/66 (26%) and multifocal in 49/66 (74%). The transition zone was involved in 29% of unifocal and 71% of multifocal tumours. Of all 66 patients, the TTV was <0.5 mL in 47 (71%), and of 59 patients with biopsy GS 3 + 3, 33 (56%) had a TTV of <0.5 mL and pathological GS 3 + 3. Of 19 patients with a TTV of > or =0.5 mL, the median TTV was 1.06 (0.51-5.05) mL, with tumour foci of transition zone origin in 16 (84%). The study was limited by its retrospective design and small sample size. CONCLUSIONS: Using conservative selection criteria for predicting LV/LG cancer, RP specimens showed organ-confined disease in all cases, upgrading to GS > or = 4 + 3 in 6%, and TTV <0.5 mL in 71% of cases. The transition zone is a common location of under-sampled disease.
Authors: Ian Thompson; James Brantley Thrasher; Gunnar Aus; Arthur L Burnett; Edith D Canby-Hagino; Michael S Cookson; Anthony V D'Amico; Roger R Dmochowski; David T Eton; Jeffrey D Forman; S Larry Goldenberg; Javier Hernandez; Celestia S Higano; Stephen R Kraus; Judd W Moul; Catherine M Tangen Journal: J Urol Date: 2007-06 Impact factor: 7.450
Authors: Michael E Chen; Dennis Johnston; Adriana O Reyes; Cindy P Soto; R Joseph Babaian; Patricia Troncoso Journal: Am J Surg Pathol Date: 2003-10 Impact factor: 6.394
Authors: Felix K-H Chun; Nazareno Suardi; Umberto Capitanio; Claudio Jeldres; Sascha Ahyai; Markus Graefen; Alexander Haese; Thomas Steuber; Andreas Erbersdobler; Francesco Montorsi; Hartwig Huland; Pierre I Karakiewicz Journal: Eur Urol Date: 2008-05-15 Impact factor: 20.096
Authors: Hiroyuki Nakanishi; Xuemei Wang; Atsushi Ochiai; Kiril Trpkov; Asli Yilmaz; J Bryan Donnelly; John W Davis; Patricia Troncoso; R Joseph Babaian Journal: Cancer Date: 2007-12-01 Impact factor: 6.860
Authors: Spyridon P Basourakos; John W Davis; Brian F Chapin; John F Ward; Curtis A Pettaway; Louis L Pisters; Neema Navai; Mary F Achim; Xuemei Wang; Hsiang-Chun Chen; Seungtaek Choi; Deborah Kuban; Patricia Troncoso; Sam Hanash; Timothy C Thompson; Jeri Kim Journal: BJU Int Date: 2017-08-16 Impact factor: 5.588
Authors: John W Davis; John F Ward; Curtis A Pettaway; Xuemei Wang; Deborah Kuban; Steven J Frank; Andrew K Lee; Louis L Pisters; Surena F Matin; Jay B Shah; Jose A Karam; Brian F Chapin; John N Papadopoulos; Mary Achim; Karen E Hoffman; Thomas J Pugh; Seungtaek Choi; Patricia Troncoso; Christopher J Logothetis; Jeri Kim Journal: BJU Int Date: 2015-07-04 Impact factor: 5.588
Authors: Qiang Fu; Judd W Moul; Lionel Bañez; Leon Sun; Vladimir Mouraviev; Donghua Xie; Thomas J Polascik Journal: Med Oncol Date: 2012-12-22 Impact factor: 3.064